AR and CAV1 |
androgen receptor |
caveolin 1, caveolae protein, 22kDa |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Metabolism of lipids and lipoproteins
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Lipid digestion, mobilization, and transport
- Signaling by Wnt
- Basigin interactions
- VEGFA-VEGFR2 Pathway
- Cell surface interactions at the vascular wall
- eNOS activation
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- Metabolism of nitric oxide
- Signaling by VEGF
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
- NOSTRIN mediated eNOS trafficking
- VEGFR2 mediated vascular permeability
- XAV939 inhibits tankyrase, stabilizing AXIN
- eNOS activation and regulation
- Signaling by WNT in cancer
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and ZMIZ1 |
androgen receptor |
zinc finger, MIZ-type containing 1 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and NCOA4 |
androgen receptor |
nuclear receptor coactivator 4 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and CREBBP |
androgen receptor |
CREB binding protein |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Metabolism of lipids and lipoproteins
- Signaling by Wnt
- Regulation of gene expression by Hypoxia-inducible Factor
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- Pre-NOTCH Transcription and Translation
- RNF mutants show enhanced WNT signaling and proliferation
- Signaling by NOTCH1 in Cancer
- Orphan transporters
- Chromatin organization
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- Factors involved in megakaryocyte development and platelet production
- Chromatin modifying enzymes
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Activation of gene expression by SREBF (SREBP)
- Transcriptional activation of mitochondrial biogenesis
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- PPARA activates gene expression
- Cellular response to hypoxia
- Organelle biogenesis and maintenance
- Regulation of Hypoxia-inducible Factor (HIF) by oxygen
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Attenuation phase
- HATs acetylate histones
- RORA activates circadian gene expression
- Regulation of cholesterol biosynthesis by SREBP (SREBF)
- HSF1-dependent transactivation
- TRAF3-dependent IRF activation pathway
- Signaling by NOTCH1
- Transcriptional regulation of white adipocyte differentiation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Pre-NOTCH Expression and Processing
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Innate Immune System
- FBXW7 Mutants and NOTCH1 in Cancer
- Fatty acid, triacylglycerol, and ketone body metabolism
- Cytosolic sensors of pathogen-associated DNA
- Cellular response to heat stress
- REV-ERBA represses gene expression
- Mitochondrial biogenesis
- Notch-HLH transcription pathway
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- NOTCH1 Intracellular Domain Regulates Transcription
- TCF dependent signaling in response to WNT
- TRAF6 mediated IRF7 activation
- YAP1- and WWTR1 (TAZ)-stimulated gene expression
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- Signaling by WNT in cancer
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and GSK3B |
androgen receptor |
glycogen synthase kinase 3 beta |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Signaling by the B Cell Receptor (BCR)
- Hedgehog 'off' state
- Signaling by FGFR in disease
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- DAP12 signaling
- Downstream signaling events of B Cell Receptor (BCR)
- Degradation of beta-catenin by the destruction complex
- PI3K/AKT activation
- PI-3K cascade
- RNF mutants show enhanced WNT signaling and proliferation
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- S33 mutants of beta-catenin aren't phosphorylated
- Beta-catenin phosphorylation cascade
- truncations of AMER1 destabilize the destruction complex
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- deletions in the AMER1 gene destabilize the destruction complex
- AMER1 mutants destabilize the destruction complex
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- PI3K/AKT Signaling in Cancer
- CRMPs in Sema3A signaling
- Adaptive Immune System
- Axon guidance
- PIP3 activates AKT signaling
- APC truncation mutants have impaired AXIN binding
- APC truncation mutants are not K63 polyubiquitinated
- disassembly of the destruction complex and recruitment of AXIN to the membrane
- S37 mutants of beta-catenin aren't phosphorylated
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- XAV939 inhibits tankyrase, stabilizing AXIN
- Innate Immune System
- Signalling by NGF
- Semaphorin interactions
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- Regulation of HSF1-mediated heat shock response
- Cellular response to heat stress
- NGF signalling via TRKA from the plasma membrane
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- TCF dependent signaling in response to WNT
- Signaling by Hedgehog
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- GLI3 is processed to GLI3R by the proteasome
- Degradation of GLI2 by the proteasome
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
- Lithium
- 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
- I-5
- N-(4-Methoxybenzyl)-N\'-(5-Nitro-1,3-Thiazol-2-Yl)Urea
- Staurosporine
- Indirubin-3\'-Monoxime
- Adenosine-5\'-Diphosphate
- (3e)-6\'-Bromo-2,3\'-Biindole-2\',3(1h,1\'h)-Dione 3-Oxime
- Alsterpaullone
- Phosphoaminophosphonic Acid-Adenylate Ester
- 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
- 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
- (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
- N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
- 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2\'H-2,3\'-biindol-2\'-one
- N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
- 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
- ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
- (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
|
|
|
AR and TGIF1 |
androgen receptor |
TGFB-induced factor homeobox 1 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Loss of Function of TGFBR2 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- TGFBR1 LBD Mutants in Cancer
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Loss of Function of TGFBR1 in Cancer
- Generic Transcription Pathway
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- SMAD4 MH2 Domain Mutants in Cancer
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and NCOR1 |
androgen receptor |
nuclear receptor corepressor 1 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Loss of Function of TGFBR2 in Cancer
- PPARA activates gene expression
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Organelle biogenesis and maintenance
- Metabolism of lipids and lipoproteins
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- RORA activates circadian gene expression
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- Signaling by NOTCH1
- Transcriptional regulation of white adipocyte differentiation
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- Fatty acid, triacylglycerol, and ketone body metabolism
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Chromatin organization
- HDACs deacetylate histones
- Loss of Function of SMAD2/3 in Cancer
- Signaling by NOTCH
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- REV-ERBA represses gene expression
- Signaling by ERBB4
- Loss of Function of TGFBR1 in Cancer
- Mitochondrial biogenesis
- NOTCH1 Intracellular Domain Regulates Transcription
- Nuclear signaling by ERBB4
- Chromatin modifying enzymes
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- Transcriptional activation of mitochondrial biogenesis
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- SMAD4 MH2 Domain Mutants in Cancer
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and NCOR2 |
androgen receptor |
nuclear receptor corepressor 2 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Loss of Function of TGFBR2 in Cancer
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Metabolism of lipids and lipoproteins
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- Signaling by NOTCH1
- Transcriptional regulation of white adipocyte differentiation
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
- TGFBR2 MSI Frameshift Mutants in Cancer
- Fatty acid, triacylglycerol, and ketone body metabolism
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Chromatin organization
- HDACs deacetylate histones
- Loss of Function of SMAD2/3 in Cancer
- Signaling by NOTCH
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- NOTCH1 Intracellular Domain Regulates Transcription
- Chromatin modifying enzymes
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- SMAD4 MH2 Domain Mutants in Cancer
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and GTF2H1 |
androgen receptor |
general transcription factor IIH, polypeptide 1, 62kDa |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- RNA Polymerase II Promoter Escape
- Formation of HIV-1 elongation complex containing HIV-1 Tat
- Nucleotide Excision Repair
- RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
- RNA Polymerase I Chain Elongation
- RNA Polymerase II Transcription
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- RNA Polymerase I Transcription Initiation
- RNA Polymerase I Promoter Clearance
- HIV Infection
- Formation of the Early Elongation Complex
- Tat-mediated elongation of the HIV-1 transcript
- Formation of transcription-coupled NER (TC-NER) repair complex
- RNA Pol II CTD phosphorylation and interaction with CE
- RNA Polymerase II Pre-transcription Events
- Dual incision reaction in TC-NER
- NoRC negatively regulates rRNA expression
- HIV Transcription Initiation
- HIV Life Cycle
- RNA Pol II CTD phosphorylation and interaction with CE
- RNA Polymerase II HIV Promoter Escape
- HIV Transcription Elongation
- Dual incision reaction in GG-NER
- mRNA Capping
- RNA Polymerase I Transcription
- RNA Polymerase I Promoter Escape
- RNA Polymerase I Transcription Termination
- Epigenetic regulation of gene expression
- Negative epigenetic regulation of rRNA expression
- Late Phase of HIV Life Cycle
- Formation of RNA Pol II elongation complex
- Global Genomic NER (GG-NER)
- RNA Polymerase II Transcription Initiation And Promoter Clearance
- Transcription-coupled NER (TC-NER)
- Formation of HIV elongation complex in the absence of HIV Tat
- Formation of the HIV-1 Early Elongation Complex
- Formation of incision complex in GG-NER
- RNA Polymerase II Transcription Initiation
- Transcription of the HIV genome
- RNA Polymerase II Transcription Elongation
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and MLH3 |
androgen receptor |
mutL homolog 3 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and SMARCA4 |
androgen receptor |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Chromatin modifying enzymes
- Chromatin organization
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- formation of the beta-catenin:TCF transactivating complex
- XAV939 inhibits tankyrase, stabilizing AXIN
- Signaling by Wnt
- Signaling by WNT in cancer
- RMTs methylate histone arginines
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and MAPK1 |
androgen receptor |
mitogen-activated protein kinase 1 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- phospho-PLA2 pathway
- Ca-dependent events
- Signaling by FGFR in disease
- Cellular Senescence
- ERKs are inactivated
- CREB phosphorylation through the activation of Ras
- Signaling by EGFRvIII in Cancer
- Toll Like Receptor TLR1:TLR2 Cascade
- Toll Like Receptor 5 (TLR5) Cascade
- Gastrin-CREB signalling pathway via PKC and MAPK
- MyD88 dependent cascade initiated on endosome
- SOS-mediated signalling
- Fcgamma receptor (FCGR) dependent phagocytosis
- SHC-mediated signalling
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Regulation of actin dynamics for phagocytic cup formation
- TRIF-mediated TLR3/TLR4 signaling
- Senescence-Associated Secretory Phenotype (SASP)
- Signaling by VEGF
- Signalling to RAS
- Downstream signal transduction
- Toll Like Receptor 3 (TLR3) Cascade
- Interleukin-2 signaling
- Platelet activation, signaling and aggregation
- Frs2-mediated activation
- Transmission across Chemical Synapses
- Axon guidance
- IRS-mediated signalling
- L1CAM interactions
- Oncogene Induced Senescence
- VEGFA-VEGFR2 Pathway
- Activated TLR4 signalling
- VEGFR2 mediated cell proliferation
- GRB2 events in ERBB2 signaling
- RSK activation
- Activation of NMDA receptor upon glutamate binding and postsynaptic events
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- NCAM signaling for neurite out-growth
- Signalling to p38 via RIT and RIN
- RAF/MAP kinase cascade
- Innate Immune System
- Signaling by Insulin receptor
- ERKs are inactivated
- Signal transduction by L1
- Insulin receptor signalling cascade
- PLC beta mediated events
- IRS-related events
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- SHC-related events
- G-protein mediated events
- Signaling by FGFR
- Thrombin signalling through proteinase activated receptors (PARs)
- ARMS-mediated activation
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Signal attenuation
- Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
- ERK/MAPK targets
- MAPK targets/ Nuclear events mediated by MAP kinases
- Signaling by GPCR
- Mitotic Prophase
- Golgi Cisternae Pericentriolar Stack Reorganization
- FCERI mediated MAPK activation
- Signaling by SCF-KIT
- SHC1 events in ERBB2 signaling
- DAP12 signaling
- Toll Like Receptor 9 (TLR9) Cascade
- ERK/MAPK targets
- Negative regulation of FGFR signaling
- Signaling by PDGF
- DAP12 interactions
- Opioid Signalling
- SHC-related events triggered by IGF1R
- GRB2 events in EGFR signaling
- Signaling by ERBB4
- Toll Like Receptor 2 (TLR2) Cascade
- Signaling by ERBB2
- Signaling by EGFR
- Signaling by Interleukins
- SHC1 events in ERBB4 signaling
- Toll Like Receptor 4 (TLR4) Cascade
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Signaling by Leptin
- Growth hormone receptor signaling
- Signalling to ERKs
- Prolonged ERK activation events
- ERK activation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- IGF1R signaling cascade
- Recycling pathway of L1
- M Phase
- Toll Like Receptor TLR6:TLR2 Cascade
- IRS-related events triggered by IGF1R
- Activation of the AP-1 family of transcription factors
- MyD88 cascade initiated on plasma membrane
- ERK activation
- Downstream signaling of activated FGFR
- Advanced glycosylation endproduct receptor signaling
- Post NMDA receptor activation events
- Signalling by NGF
- SOS-mediated signalling
- MAP kinase activation in TLR cascade
- SHC-mediated signalling
- Cytokine Signaling in Immune system
- Cellular response to heat stress
- Regulation of HSF1-mediated heat shock response
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Cell Cycle, Mitotic
- ERK2 activation
- SHC1 events in EGFR signaling
- FRS2-mediated cascade
- IRS-mediated signalling
- Oxidative Stress Induced Senescence
- ERK2 activation
- Nuclear Events (kinase and transcription factor activation)
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
- Isoproterenol
- Arsenic trioxide
- Olomoucine
- Phosphonothreonine
- Purvalanol
- SB220025
- N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE
- (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
- (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE
- 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE
- (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
- 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
|
|
|
AR and EP300 |
androgen receptor |
E1A binding protein p300 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Metabolism of lipids and lipoproteins
- Signaling by Wnt
- NOTCH2 intracellular domain regulates transcription
- Regulation of gene expression by Hypoxia-inducible Factor
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Signaling by NOTCH2
- Pre-NOTCH Transcription and Translation
- RNF mutants show enhanced WNT signaling and proliferation
- Signaling by NOTCH1 in Cancer
- Chromatin organization
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- Factors involved in megakaryocyte development and platelet production
- Chromatin modifying enzymes
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Mitotic G2-G2/M phases
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- PPARA activates gene expression
- Cellular response to hypoxia
- Regulation of Hypoxia-inducible Factor (HIF) by oxygen
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Attenuation phase
- G2/M Transition
- HATs acetylate histones
- RORA activates circadian gene expression
- HSF1-dependent transactivation
- TRAF3-dependent IRF activation pathway
- Signaling by NOTCH1
- Transcriptional regulation of white adipocyte differentiation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Pre-NOTCH Expression and Processing
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
- Innate Immune System
- Fatty acid, triacylglycerol, and ketone body metabolism
- Cytosolic sensors of pathogen-associated DNA
- Cellular response to heat stress
- REV-ERBA represses gene expression
- Cell Cycle, Mitotic
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- NOTCH1 Intracellular Domain Regulates Transcription
- TCF dependent signaling in response to WNT
- TRAF6 mediated IRF7 activation
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- Signaling by WNT in cancer
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- Polo-like kinase mediated events
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and SMAD3 |
androgen receptor |
SMAD family member 3 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
AR and HDAC1 |
androgen receptor |
histone deacetylase 1 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Loss of Function of TGFBR2 in Cancer
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- misspliced GSK3beta mutants stabilize beta-catenin
- T41 mutants of beta-catenin aren't phosphorylated
- SMAD2/3 MH2 Domain Mutants in Cancer
- TCF7L2 mutants don't bind CTBP
- truncated APC mutants destabilize the destruction complex
- Signaling by Wnt
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Degradation of beta-catenin by the destruction complex
- NoRC negatively regulates rRNA expression
- Generic Transcription Pathway
- S33 mutants of beta-catenin aren't phosphorylated
- AXIN mutants destabilize the destruction complex, activating WNT signaling
- RNF mutants show enhanced WNT signaling and proliferation
- Signaling by NOTCH1 in Cancer
- Mitotic G1-G1/S phases
- truncations of AMER1 destabilize the destruction complex
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Chromatin organization
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
- Loss of Function of SMAD4 in Cancer
- AXIN missense mutants destabilize the destruction complex
- S45 mutants of beta-catenin aren't phosphorylated
- TGFBR1 KD Mutants in Cancer
- Factors involved in megakaryocyte development and platelet production
- Chromatin modifying enzymes
- deletions in the AMER1 gene destabilize the destruction complex
- AMER1 mutants destabilize the destruction complex
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- RNA Polymerase I Transcription Initiation
- APC truncation mutants have impaired AXIN binding
- RNA Polymerase I Promoter Clearance
- TGFBR1 LBD Mutants in Cancer
- deactivation of the beta-catenin transactivating complex
- APC truncation mutants are not K63 polyubiquitinated
- S37 mutants of beta-catenin aren't phosphorylated
- Signaling by NOTCH1
- XAV939 inhibits tankyrase, stabilizing AXIN
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
- Signalling by NGF
- HDACs deacetylate histones
- p75NTR negatively regulates cell cycle via SC1
- Loss of Function of SMAD2/3 in Cancer
- RNA Polymerase I Transcription
- TGFBR2 Kinase Domain Mutants in Cancer
- Epigenetic regulation of gene expression
- p75 NTR receptor-mediated signalling
- G0 and Early G1
- Negative epigenetic regulation of rRNA expression
- repression of WNT target genes
- Loss of Function of TGFBR1 in Cancer
- Cell Cycle, Mitotic
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- TCF dependent signaling in response to WNT
- deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
- Signaling by WNT in cancer
- SMAD4 MH2 Domain Mutants in Cancer
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
RHOA and ITPR1 |
ras homolog family member A |
inositol 1,4,5-trisphosphate receptor, type 1 |
- Loss of Function of TGFBR2 in Cancer
- Signaling by GPCR
- Axon guidance
- Axonal growth stimulation
- SMAD2/3 MH2 Domain Mutants in Cancer
- Signaling by Wnt
- TGFBR1 LBD Mutants in Cancer
- VEGFA-VEGFR2 Pathway
- EPHB-mediated forward signaling
- Rho GTPase cycle
- EPHA-mediated growth cone collapse
- Axonal growth inhibition (RHOA activation)
- PI3K/AKT activation
- G beta:gamma signalling through PI3Kgamma
- EPH-Ephrin signaling
- G alpha (12/13) signalling events
- Sema4D mediated inhibition of cell attachment and migration
- Sema4D in semaphorin signaling
- Sema4D induced cell migration and growth-cone collapse
- TGFBR2 MSI Frameshift Mutants in Cancer
- Signalling by NGF
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- p75NTR regulates axonogenesis
- G-protein beta:gamma signalling
- Loss of Function of SMAD2/3 in Cancer
- Semaphorin interactions
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- p75 NTR receptor-mediated signalling
- TGFBR1 KD Mutants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Loss of Function of TGFBR1 in Cancer
- beta-catenin independent WNT signaling
- GPCR downstream signaling
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by VEGF
- Signaling by Rho GTPases
- GPVI-mediated activation cascade
- Platelet activation, signaling and aggregation
- PCP/CE pathway
- SMAD4 MH2 Domain Mutants in Cancer
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by GPCR
- Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
- Phospholipase C-mediated cascade
- Signaling by FGFR in disease
- Integration of energy metabolism
- cGMP effects
- Signaling by Wnt
- Signaling by EGFRvIII in Cancer
- PLCG1 events in ERBB2 signaling
- Effects of PIP2 hydrolysis
- Platelet calcium homeostasis
- DAP12 signaling
- Gastrin-CREB signalling pathway via PKC and MAPK
- Role of phospholipids in phagocytosis
- Fcgamma receptor (FCGR) dependent phagocytosis
- Signaling by PDGF
- DAP12 interactions
- Opioid Signalling
- EGFR interacts with phospholipase C-gamma
- Signaling by ERBB2
- G alpha (q) signalling events
- Signaling by EGFR
- GPCR downstream signaling
- Platelet homeostasis
- Signaling by VEGF
- Downstream signal transduction
- Fc epsilon receptor (FCERI) signaling
- Signaling by EGFR in Cancer
- Platelet activation, signaling and aggregation
- Adaptive Immune System
- G alpha (q) signalling events
- DAG and IP3 signaling
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated cell proliferation
- Downstream signaling of activated FGFR
- Nitric oxide stimulates guanylate cyclase
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Innate Immune System
- Signalling by NGF
- PLC beta mediated events
- Regulation of insulin secretion
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- G-protein mediated events
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- beta-catenin independent WNT signaling
- Signaling by FGFR
- Ca2+ pathway
- Elevation of cytosolic Ca2+ levels
- PLC-gamma1 signalling
- FCERI mediated Ca+2 mobilization
|
- Guanosine-5\'-Diphosphate
|
|
|
|
RHOA and SMAD2 |
ras homolog family member A |
SMAD family member 2 |
- Loss of Function of TGFBR2 in Cancer
- Signaling by GPCR
- Axon guidance
- Axonal growth stimulation
- SMAD2/3 MH2 Domain Mutants in Cancer
- Signaling by Wnt
- TGFBR1 LBD Mutants in Cancer
- VEGFA-VEGFR2 Pathway
- EPHB-mediated forward signaling
- Rho GTPase cycle
- EPHA-mediated growth cone collapse
- Axonal growth inhibition (RHOA activation)
- PI3K/AKT activation
- G beta:gamma signalling through PI3Kgamma
- EPH-Ephrin signaling
- G alpha (12/13) signalling events
- Sema4D mediated inhibition of cell attachment and migration
- Sema4D in semaphorin signaling
- Sema4D induced cell migration and growth-cone collapse
- TGFBR2 MSI Frameshift Mutants in Cancer
- Signalling by NGF
- TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- p75NTR regulates axonogenesis
- G-protein beta:gamma signalling
- Loss of Function of SMAD2/3 in Cancer
- Semaphorin interactions
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- p75 NTR receptor-mediated signalling
- TGFBR1 KD Mutants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Loss of Function of TGFBR1 in Cancer
- beta-catenin independent WNT signaling
- GPCR downstream signaling
- Signaling by TGF-beta Receptor Complex
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by VEGF
- Signaling by Rho GTPases
- GPVI-mediated activation cascade
- Platelet activation, signaling and aggregation
- PCP/CE pathway
- SMAD4 MH2 Domain Mutants in Cancer
|
- Loss of Function of TGFBR2 in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- TGFBR1 LBD Mutants in Cancer
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
- Generic Transcription Pathway
- Signaling by NODAL
- TGFBR2 MSI Frameshift Mutants in Cancer
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- Loss of Function of SMAD2/3 in Cancer
- Signaling by Activin
- TGFBR2 Kinase Domain Mutants in Cancer
- Loss of Function of SMAD4 in Cancer
- TGFBR1 KD Mutants in Cancer
- Loss of Function of TGFBR1 in Cancer
- Signaling by TGF-beta Receptor Complex in Cancer
- Signaling by TGF-beta Receptor Complex
- SMAD4 MH2 Domain Mutants in Cancer
|
- Guanosine-5\'-Diphosphate
|
|
|
|
ARRB2 and MDM2 |
arrestin, beta 2 |
MDM2 proto-oncogene, E3 ubiquitin protein ligase |
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Signaling by NOTCH
- Signaling by Wnt
- beta-catenin independent WNT signaling
- Thrombin signalling through proteinase activated receptors (PARs)
- Activated NOTCH1 Transmits Signal to the Nucleus
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Hedgehog 'on' state
- Signaling by NOTCH1
- WNT5A-dependent internalization of FZD4
- Signaling by Hedgehog
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by NOTCH1 in Cancer
- Platelet activation, signaling and aggregation
- PCP/CE pathway
- Activation of SMO
- FBXW7 Mutants and NOTCH1 in Cancer
|
- Signaling by the B Cell Receptor (BCR)
- Signaling by FGFR in disease
- Cellular Senescence
- p53-Dependent G1/S DNA damage checkpoint
- AKT phosphorylates targets in the cytosol
- Signaling by EGFRvIII in Cancer
- Signaling by SCF-KIT
- Downstream signaling events of B Cell Receptor (BCR)
- DAP12 signaling
- PI3K/AKT activation
- PI-3K cascade
- Stabilization of p53
- Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
- Signaling by PDGF
- DAP12 interactions
- GAB1 signalosome
- Signaling by ERBB4
- Constitutive PI3K/AKT Signaling in Cancer
- Role of LAT2/NTAL/LAB on calcium mobilization
- PI3K events in ERBB4 signaling
- Signaling by ERBB2
- Signaling by EGFR
- Downstream signal transduction
- Signaling by EGFR in Cancer
- Fc epsilon receptor (FCERI) signaling
- PI3K/AKT Signaling in Cancer
- Adaptive Immune System
- Transmission across Chemical Synapses
- PIP3 activates AKT signaling
- Oncogene Induced Senescence
- p53-Dependent G1 DNA Damage Response
- PI3K events in ERBB2 signaling
- Downstream signaling of activated FGFR
- G1/S DNA Damage Checkpoints
- Innate Immune System
- Signalling by NGF
- Signaling by Ligand-Responsive EGFR Variants in Cancer
- NGF signalling via TRKA from the plasma membrane
- Trafficking of AMPA receptors
- Signaling by Overexpressed Wild-Type EGFR in Cancer
- Signaling by FGFR
- Oxidative Stress Induced Senescence
- Cell Cycle Checkpoints
- Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
|
|
- Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
- Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
|
|
|
ATF1 and BRCA1 |
activating transcription factor 1 |
breast cancer 1, early onset |
- CREB phosphorylation
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- CREB phosphorylation
- Toll Like Receptor TLR6:TLR2 Cascade
- Activated TLR4 signalling
- Toll Like Receptor TLR1:TLR2 Cascade
- MyD88 cascade initiated on plasma membrane
- Toll Like Receptor 5 (TLR5) Cascade
- MyD88 dependent cascade initiated on endosome
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- Toll Like Receptor 9 (TLR9) Cascade
- Innate Immune System
- Signalling by NGF
- TRIF-mediated TLR3/TLR4 signaling
- MAP kinase activation in TLR cascade
- NGF signalling via TRKA from the plasma membrane
- MyD88-independent cascade
- Toll Like Receptor 2 (TLR2) Cascade
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- MAPK targets/ Nuclear events mediated by MAP kinases
- Nuclear Events (kinase and transcription factor activation)
|
- ATM mediated phosphorylation of repair proteins
- Meiotic recombination
- Fanconi Anemia pathway
- ATM mediated response to DNA double-strand break
- Homologous Recombination Repair
- Meiotic synapsis
- Homologous recombination repair of replication-independent double-strand breaks
- Recruitment of repair and signaling proteins to double-strand breaks
- Double-Strand Break Repair
|
|
|
|
|
ATM and BRCA2 |
ATM serine/threonine kinase |
breast cancer 2, early onset |
- Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
- Fanconi Anemia pathway
- G2/M Checkpoints
- Cellular Senescence
- p53-Dependent G1/S DNA damage checkpoint
- p53-Dependent G1 DNA Damage Response
- Regulation of the Fanconi anemia pathway
- Stabilization of p53
- p53-Independent DNA Damage Response
- Homologous recombination repair of replication-independent double-strand breaks
- p53-Independent G1/S DNA damage checkpoint
- Double-Strand Break Repair
- G1/S DNA Damage Checkpoints
- ATM mediated phosphorylation of repair proteins
- DNA Damage/Telomere Stress Induced Senescence
- Meiotic recombination
- ATM mediated response to DNA double-strand break
- G2/M DNA damage checkpoint
- Regulation of HSF1-mediated heat shock response
- Cellular response to heat stress
- Autodegradation of the E3 ubiquitin ligase COP1
- Homologous Recombination Repair
- Recruitment of repair and signaling proteins to double-strand breaks
- Cell Cycle Checkpoints
|
- Homologous DNA pairing and strand exchange
- Meiotic recombination
- Fanconi Anemia pathway
- Homologous Recombination Repair
- Homologous recombination repair of replication-independent double-strand breaks
- Double-Strand Break Repair
- Presynaptic phase of homologous DNA pairing and strand exchange
|
|
|
|
|